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Herbal medicines are currently in high demand, and their popularity is steadily 
increasing. Because of their perceived effectiveness, fewer side effects, and relatively 
low cost, they are being used for the management of numerous medical conditions. 
However, they are capable of affecting the pharmacokinetics and pharmacodynamics of 
co-administered conventional drugs. These interactions are particularly of clinically 
relevance when metabolizing enzymes and xenobiotic transporters, which are 
responsible for fate of many drugs, are induced or inhibited, sometimes resulting in 
unexpected outcomes.  
The main focus of this article is an evidence for pharmacokinetic herb-drug interactions. 
A review of literature reporting herbal medicines, their effects and documented 
interactions with conventional drugs was conducted between January 2012 and June 
2015 on research databases. Relevant studies were identified through searches of 
electronic databases, citations, reference lists, comprehensive pearl growing and 
handsearching related journals and conference proceedings. The relevant online 
databases (including PubMed, Cochrane database, Google Scholar and Web of Science) 
were utilised using online keyword searches, with searches limited by date to reports 
published from 1985 onwards. 
This paper discusses the general use of herbal medicines in the management of several 
ailments, their concurrent use with conventional therapy, mechanisms underlying 
herb-drug interactions (HDIs) as well as the draw-backs of herbal remedy use. The 
authors also suggest means of surveillance and safety monitoring of herbal medicines. 
Contrary to popular belief that “herbal medicines are totally safe”, we are of the view that 
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they are capable of causing significant toxic effects and altered pharmaceutical outcomes 
when co-administered with conventional medicines. Due to the paucity of information as 
well as the sometimes conflicting reports on HDIs, much more research in this field is 
needed. The authors further suggest the need to standardize and better regulate herbal 
medicines in order to ensure their safety and efficacy, when used alone or in combination 
with conventional drugs.  
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1. Overview of herbal medicine use  
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Herbal medicine comprises the use of plant parts for medicinal purposes. Unlike 
conventional drugs, most herbal medicines are a complex mixture of chemical 
constituents whose bioactive components in many instances are yet to be fully 
characterized, but have been reported to be medicinally efficacious  [1]. There is a long 
history of the use of these phytomedicines, with herbalism having a long tradition of use 
outside of conventional medicine. Their use has become more established as 
improvements in analysis and quality control as well as advances in clinical research 
has shown their value in treating and preventing disease [2]. In some developing 
countries, up to 80 % of the indigenous populace are known to depend on traditional 
systems of medicine and medicinal plants as their primary source of healthcare [3, 
4].  This occurrence is not significantly different across the globe. For instance, reports 
show that over 70% of German physicians prescribe herbal medicines and over 75% of 
the German populace have used complementary or natural medicine [5]. In countries 
like the United States, an increase in their use has been reported due to dissatisfaction 
with the cost of prescription medications, combined with an interest in returning to 
natural or organic medicines [6].  In Japan, about 148 kinds of Japanese herbal 
medicines (Kampo medicines) have been approved and are enlisted on the National 
Health Insurance Drug Tariff. These medicines are reportedly prescribed by 72-78% of 
Japanese physicians [7, 8]. These plant-based medicines are believed to be increasingly 
utilized because of their low cost, perceived safety, efficacy and lower incidence of 
adverse effects when compared to orthodox medicines. While their use is on the 
increase in some countries, stringent regulatory requirements in other countries make it 
difficult to register herbal medicines, therefore their reported limited use [9]. In the 
United Kingdom, herbal medicines have been recognized as substances that pose 
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particular challenges for public health and effective regulation is being sought which 
would safeguard the public. To this end, there have been deliberations on the need for 
statutory regulation of UK herbal medicine and its practitioners [10, 11].. It is worthy 
to note that approximately 30-50% of conventional medicines in use evolved from 
natural products from where they are synthesized as pharmaceutical preparations 
[12-14]. In particular are the medicines Catharanthus roseus (vincristine), Atropa 
belladonna (atropine), Cinchona sp. (quinine), Cephaelis ipecacuanha (emetine), 
Digitalis purpurea (digitoxin and digoxin), Ephedra sinica (ephedrine), (Artemisia 
annua (artemisinin), Rauwolfia serpentine (reserpine), Podophyllum peltatum 
(etoposide) among several others.  
2. Mechanisms of herb-drug interactions 
Similar to conventional pharmaceutical products, pharmacokinetic and 
pharmacodynamic alterations are the two mechanistic pathways through which 
herb-drug interactions (HDIs) occur, resulting in null, beneficial or toxic responses 
(Figure 1). In addition to the cytochrome enzymes, membrane transporters are known 
play an important role in the modulation of absorption, distribution, metabolism and 
excretion of drugs [15]. These HDIs arise from changes in the function and expression 
of transporters or enzymes that mediate the absorption and elimination of drugs in the 
small intestine, kidney and liver [16].  
2.1 Enzyme-mediated HDIs 
One of the most important causes of clinically-relevant HDIs is the inhibition or 
induction of the activity of cytochrome P450, a superfamily of enzymes catalyzing an 
extremely diverse and often complex reactions in the metabolism of numerous drugs, 
phytomedicines and xenobiotics. P450s are the main enzymes involved in drug 
6 
 
metabolism, with the majority of drugs interacting with the CYP 3A isoform [17, 18]. 
For instance, several intestinal CYP 3A inhibitors (including the triterpenes; maslinic 
acid, corosolic acid, and ursolic acid) have been isolated from Vaccinium macrocarpon 
(cranberry) [19]. Cranberry is now commonly taken as a treatment for urinary tract 
infections due to a group of proanthocyanidins which exhibit bacterial anti-adhesion 
activity against both antibiotic susceptible and resistant strains of uropathogenic 
Escherichia coli bacteria [19, 20].  Another study revealed that cranberry juice inhibits 
the CYP3A-mediated metabolism of nifedipine altering its pharmacokinetics by 
increasing the concentration of nifedipine in rat plasma [21]. The study demonstrated 
that the oxidative activities of nifedipine in rat intestinal and human hepatic microsomes 
were inhibited after pre-incubation with cranberry juice [21]. However, a clinical study 
in 10 healthy volunteers involving the CYP3A probe substrate; midazolam and a 
cranberry juice product suggested that interaction was unlikely [22]. However, in a 
more recent study that utilized a systematic approach, from in vitro assay (Caco-2 cell 
and human intestinal microsomes) to a clinical study in 16 healthy volunteers, it was 
observed that a cranberry juice product revealed a pharmacokinetic interaction with 
midazolam [23]. The difference in the finding of these studies suggests the importance 
of utilizing clinical regimens and taking into consideration the interbrand variation of 
natural products in the design of pharmacokinetic studies. Similarly, the widely used 
herbal remedy, Echinacea purpurea (Echinacea) has been reported to significantly 
induce CYP 3A [24]. It has been shown to selectively modulate the catalytic activity of 
CYP3A at hepatic and intestinal sites, suggesting that CYP 3A substrates with relatively 
high bioavailability may be more susceptible to Echinacea-mediated interactions [25, 
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26]. As CYP 3A is the main drug metabolizing enzyme, the potential of HDIs occurring 
with Echinacea purpurea may be high. 
2.2 Transporter-mediated HDIs 
Although most studies have focused on cytochrome-based drug interactions, the 
influence of transporters as a mechanism for HDIs is increasingly being documented, as 
it has been revealed that they can play an important role in modulating drug absorption, 
distribution, metabolism and elimination. Figure 2 illustrates the distribution of relevant 
transporters in the main organs responsible for drug disposition. Xenobiotic transporters 
are generally categorized into the ATP binding cassette (ABC) and solute carrier (SLC) 
superfamilies.    
2.2.1 ATP Binding Cassette-based HDIs 
ABC transporters function as barrier proteins extruding toxins and xenobiotics out of 
cells. They include p-glycoprotein (P-gp), breast cancer resistance protein (BCRP), bile 
salt export pump (BSEP) as well as several multidrug-associated resistance proteins 
(MRPs). They are commonly expressed on barrier epithelia where they mediate 
transport across cell membranes [15]. These transporters are significant determinants of 
the pharmacokinetics, efficacy and toxicity of xenobiotics (including phytomedicines) 
and co-administered drugs may inactivate, inhibit or induce these transporters. Of all the 
transporter-mediated HDIs, P-gp based interactions are the most studied. There are 
reports on the modulation of P-gp by herbs such as Hypericum perforatum (St. John’s 
wort), Vernonia amygdalina (Bitter leaf), Tapinanthus sessilifolius (African mistletoe), 
Coptis chinensis (Chinese goldthread), Ginkgo biloba (Maidenhair tree), Piper nigrum 
(Black pepper) and Glycorrhiza glabra (Licorice) [16, 27, 28].   
2.2.2 Solute Carrier-based HDIs 
8 
 
The solute carrier (SLC) transporters mainly comprise of uptake transporters including 
the organic anion transporting polypeptides (OATPs), organic cation transporters 
(OCTs), organic anion transporters (OATs), peptide transporters (PEPT) and multidrug 
and toxic compound extrusion transporters (MATE) [15]. These SLC transporters are 
known to facilitate absorption of phytomedicines and xenobiotics into the systemic 
circulation. Because transporters are mainly expressed in the intestinal epithelial cells 
and organs of elimination (kidney proximal tubules and liver hepatocytes), they can 
significantly influence the disposition of herbal medicines [29]. Fewer reports 
investigate the influence of SLC-mediated herb-drug interactions when compared to 
ABC transporters, where majority of the studies examine the interaction with P-gp [30]. 
However, several interesting drug–food interactions with fruit juices, involving uptake 
transporters have been reported [31, 32]. For instance, grapefruit juice inhibition of 
OATP resulted in reduced blood levels of fexofenadine, celiprolol, talinolol and 
acebutolol [33]. On the contrary, concurrent intake of grapefruit juice has been shown to 
increase the in vivo plasma concentrations of many drugs. This has been attributed to 
various factors, including, the inhibition of P-gp and an inhibition of intestinal CYP3A4, 
resulting in an increase in the fraction of drug absorbed [34].  Other clinical reports on 
SLC transporters include a study in healthy volunteers on baicalin from Radix 
scutellariae (Baikal skullcap), which showed a reduction in the plasma concentration of 
co-administered rosuvastatin as a result of OATP modulation [35]. In the study, the 
observed decrease in the plasma concentration of rosuvastatin in the presence of 
baicalin was thought to be partially mediated by baicalin’s induction of hepatic 
rosuvastatin uptake through OATP1B1 [35]. A study in rats reported that the 
pharmacokinetic disposition of salvianolic acid B was altered by rifampicin due to the 
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inhibition of Oatp-mediated influx [36]. Salvianolic acid B is one of the most bioactive 
components of Salvia miltiorrhiza (Red sage), a traditional Chinese herbal medicine that 
is commonly used for prevention and treatment of cerebrovascular and cardiovascular 
disorders. Likewise, herbs modulating OAT1, a transporter actively involved in renal 
active secretion have been reported [37]. Among several Chinese herbal medicines 
examined in the study, two exhibited significant inhibitions on hOAT1-mediated 
[3H]-p-amino hippuric acid uptake in vitro as well as p-amino hippuric acid clearance 
and net secretion in vivo [37]. 
2.3 Dual enzyme- and transporter-mediated HDIs 
Some phytomedicines are known to influence both transporter and cytochrome enzyme 
function. P-gp and CYP 3A4 both constitute a highly efficient barrier for many orally 
absorbed drugs with a wide overlap in their substrates [38]. Rhodiola rosea (Golden 
root), a herbal medicine used in the management of  depression has shown potent 
inhibition of both P-gp and CYP 3A4 [39]. Also, St. John’s wort (Hypericum 
perforatum), one of the most widely used herbal medicines with several medicinal 
effects including its recognized antidepressant properties, induces both CYP 3A and the 
efflux transporter; P-gp [40]. A recent study revealed that quercetin and rutin which are 
popular herbal flavonoids, induced the functions of both P-gp and CYP3A4 by 
decreasing the bioavailability of co-administered cyclosporin [41]. These alterations on 
normal P-gp efflux and CYP activity has an impact on the pharmacokinetic disposition 
of CYP 3A and P-gp substrate drugs when co-administered leading to changes, 
including lower efficacy and/or the emergence of toxicity [42]. 
2.4  Influence on transcriptional regulators 
10 
 
Several CYPs and transporters that influence drug disposition can be induced by 
xenobiotics and herbs [43]. The nuclear receptors; pregnane X receptor (PXR) and 
constitutive androstane receptor (CAR) which are present in the small intestine and liver 
have emerged as transcriptional regulators of cytochrome P450 isoenzymes (especially 
CYP 3A, -2B6, -2C8, -2C9 and -2C19) and drug transporters: P-gp, MRP2 and OATP 
[44, 45]. Besides the various xenobiotics that have been reported to activate PXR, 
herbals including St. John’s Wort are known to potently induce it [46].  These nuclear 
receptors have also been reported to enhance the expression of phase II conjugating 
enzymes like UDP-glucuronosyl transferase, sulfotransferase and 
glutathione-S-transferase enzymes [47, 48]. As a result of an increased induction of 
these nuclear receptors, there is an enhanced expression of P-gp and CYP enzymes 
which are likely to reduce the rate of absorption and increase the rate of elimination of 
drug substrates. 
3. Herbal medicine use and interactions with conventional drugs 
Several evidence-based studies on clinically relevant HDIs have been documented. 
Table 1 summarizes some clinically significant herb-drug interactions. 
3.1 Cancer 
Because of the high global incidence of cancer, the use of herbal medicines by cancer 
patients is quite common with an increasing number of cancer patients making use of 
complementary and alternative medicines in combination with their conventional 
chemotherapeutic treatment [49]. Among cancer patients in general, between 7- 48 % 
have reported taking herbal medicines [50]. These herbal medicines are used by cancer 
patients with the belief that they are capable of killing tumor cells, improving 
cancer-related symptoms as well as reducing the adverse drug effects posed by the 
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therapy [51]. However, in order to appropriately integrate herbal medicine use into 
conventional cancer therapy, pharmacological and clinical studies must be carried out 
on these herbals, with relevant monitoring for the emergence of adverse effects [52]. 
This is of particular importance as several chemotherapeutic agents are known to have 
considerable inter-individual pharmacokinetic variability which coupled with their 
narrow therapeutic index, may pose a higher risk for the occurrence of toxic HDIs. For 
instance, St John’s wort has been reported to induce the metabolism of imatinib, an 
oncolytic used in the management of chronic myelogenous leukemia and 
gastrointestinal stromal tumors. These studies showed an alteration in the 
pharmacokinetics of imatinib when co-administered with St John’s wort due to an 
induction of CYP 3A [53, 54]. This induction of CYP isoenzymes and drug transporters 
would often lead to therapeutic failure as a result of a lower plasma level of the 
anticancer drugs [49]. Likewise, a pharmacodynamic interaction involving irinotecan 
(a potent anticancer drug for the management of advanced colon cancer), which may 
cause severe diarrhea as an adverse effect has been reported to have worsened diarrhea 
on co-administration with St John’s wort through down-regulation of intestinal 
pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis [55]. In 
another study, the metabolism and toxicity of irinotecan was altered on 
co-administration with St John’s wort  with a compromise in overall antitumor activity 
[56]. Grapefruit juice intake has been reported to alter the pharmacokinetics of the 
cytotoxic drug; etoposide, with a clinical study revealing a 26.2% decrease in the AUC 
of etoposide after oral administration. It was postulated that the alteration of intestinal 
P-gp mediated transport was a possible explanation for the observed eﬀect [57]. Several 
in vitro studies have been reported with pointers to the possibility of relevant herb-drug 
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interactions. For example, Ginsenoside Rh2 from Panax ginseng significantly enhanced 
the cytotoxicity of daunomycin and vinblastine in adriamycin resistant P388 leukaemia 
cells [58]. Another pharmacologically active constituent from Panax ginseng, 
Ginsenoside Rg3 inhibited the efflux of vinblastine and reversed resistance to 
doxorubicin and vincristine in drug resistant KBV20C cells [59]. Competition of 
Ginsenoside Rg3 for binding to P-gp was demonstrated as the mechanism for the 
inhibition of drug efflux. The study showed that ginsenoside Rg3 was an effective 
modulator in restoring the sensitivity of resistant cells to doxorubicin, vincristine, 
etoposide and colchicine in human P-gp MDR cells at concentrations of 5 to 40 μM [59]. 
Although no clinical report on drug interaction studies involving ginseng and P-gp 
substrates are known, these in vitro studies on its P-gp blockade role may point to its 
beneficial function as a natural multidrug resistance reversal agent [60]. 
Also on a positive note, because of the hepatotoxicity caused by some conventional 
anticancer drugs, herbal medicines including; Punica granatum (pomegranate), 
Phyllanthus emblica (Indian gooseberry), Mangifera indica (mango), Acacia catechu 
(Black cutch) and Camellia sinensis (Tea) have been used for their hepatoprotective and 
antioxidant property when hepatotoxic chemotherapeutic agents are utilized [61]. Other 
herbal medicines used frequently by cancer patients include Zingiber officinale (ginger), 
Ginkgo biloba (ginkgo), Piper methysticum (kava-kava), quercetin (from several plants 
and also honey), Panax sp (ginseng), Curcuma longa (curcumin), Viscum album 
(European mistletoe), beta-carotene (especially from Daucus carota), Glycyrrhiza 
glabra( licorice), Astragalus membranaceus (astragalus), Viscum album (mistletoe), 
Echinacea sp. (echinacea), Berberis aristata (Indian barberry) and Allium sativum 
(garlic). These medications are perceived to be non-toxic, alleviate the symptoms 
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of cancer, boost the immune system, manage the adverse effects of chemotherapeutics, 
or may even tackle the cancer itself [27, 62]. On the whole, further research is required 
to prevent therapeutic failure and toxicity in cancer patients when herbal medicines are 
concurrently taken with conventional medicines. This would aid in establishing 
guidelines for their concomitant use. 
3.2 HIV/AIDS 
Around the world, the HIV epidemic rages on, emerging the greatest challenge 
to global health. However, AIDS-related deaths are decreasing largely due to increased 
access to treatment.  Herbal medicines are widely used by HIV patients to complement 
conventional therapy, with an increasing number of studies investigating their use in 
HIV management [63]. Common herbal medicines used during HIV management 
include Allium Sativum (garlic), Eucalyptus globulus (Blue gum), Aloe vera, 
Trigonostema xyphophylloides, Vatica astrotricha, Vernonia amygdalina (Bitterleaf), 
Lippia javanica (Fever tree), Bidens pilosa (Blackjack), Peltoforum africanum 
(Weeping wattle), Hypoxis hemerocallidea (African star grass) and Moringa oleifera 
(Drumstick tree) [16, 64, 65]. However, it is of importance to thoroughly investigate the 
potential alterations in pharmacokinetic and toxicological profiles when they are 
co-administered with conventional medicines as their concurrent use has resulted in 
beneficial and/or detrimental effects. For instance, an in vitro study revealed that 
Sutherlandia frutescens (Cancer bush) inhibited the metabolism of atazanavir in human 
liver microsomes, and may have important implications on the absorption and 
metabolism and the overall oral bioavailability of atazanavir [66]. Also the HIV 
protease inhibitor; ritonavir on co-administration with some herbal components has 
been shown to modulate both P-gp and CYP 3A4. In particular, the herbal constituents; 
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kaempferol and quercetin (from several plants), hypericin (from Hypericum perforatum) 
and allicin (from Allium sativum) have been shown to inhibit the in vitro efflux and 
CYP3A4-mediated metabolism of xenobiotics and may interact with HIV antiretrovirals 
that are P-gp or CYP 3A4 substrates, such as ritonavir [67]. Also, a clinical study in 
healthy volunteers demonstrated that St. John's wort potently altered the 
pharmacokinetics of indinavir (a protease inhibitor and a known CYP450 substrate) via 
induction of CYP 3A by St. John's wort. As illustrated in Figure 3, the study revealed a 
large reduction in indinavir concentrations by concomitant St John's wort. This finding 
has important clinical implications for HIV-infected patients receiving the two agents 
since low plasma concentrations of protease inhibitors are a cause of antiretroviral 
resistance and treatment failure [68].  Garlic is another herbal remedy commonly 
utilized by HIV/AIDS patients. Although some studies have shown that garlic has the 
potential to induce CYP isoenzymes consequently reducing the effectiveness of 
antiretroviral drugs, in vitro assessments of its effect on CYP450 are conflicting [69, 70]. 
In a clinical study, garlic was shown to reduce the plasma pharmacokinetic 
concentrations of saquinavir by altering CYP3A4 isoform of the CYP450 enzyme 
system, the isozyme through which saquinavir is metabolized, recommending patient 
caution on concomitant administration [71]. Another study in healthy volunteers 
examining the effect of an odourless garlic product indicated an insignificant reduction 
in the AUC and plasma concentrations of ritonavir following short-term garlic 
consumption [72].  This is thought to arise from transitory induction followed by 
inhibition on the various drug disposition pathways of ritonavir especially as the 
treatment duration of garlic (twice daily for 4 days) was too short to observe a 
significant change in ritonavir plasma levels [72]. This informs the need for caution, 
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especially if large quantities of raw or processed garlic are concomitantly taken with 
any protease inhibitor. Another study in healthy human subjects indicated a significant 
increase in bioavailability and maximum plasma concentration of nevirapine following 
6 days of piperine intake [73]. Piperine is a major component of Piper nigrum and Piper 
longum (black pepper and long pepper respectively) and has been reported to inhibit 
drug-metabolizing enzymes and increase the plasma concentrations of several drugs, 
including P-gp substrates [74]. 
3.3 Malaria 
Malaria is an important global public health issue with high morbidity and mortality 
rates. Majority of malarial endemic regions are from the world’s developing economies. 
As a result of the relatively high costs for conventional antimalarials, many patients are 
known to take herbal medicines for its prevention and treatment [75]. Herbal medicines 
commonly used in the management of malaria include Vernonia amygdalina (Bitterleaf), 
Piper longum (Long pepper), Tapinanthus sessilifolius (African mistletoe), leaves of 
Carica papaya (Pawpaw), leaves and bark of Azadiractha indica (Neem) and rhizomes 
of Curcuma longa (turmeric) [76]. Sometimes these herbs are used alone or in 
combination with orthodox medicines. A study based on an in vitro (Caco-2 cell), ex 
vivo (Ussing chamber) and an in vivo rat model revealed that extracts of Vernonia 
amygdalina, Tapinanthus sessilifolius and Carica papaya which are herbals commonly 
used in traditional malaria, cancer and diabetes therapy inhibited P-gp mediated digoxin 
transport [28, 77]. Findings from that study suggested that caution should be observed 
when those herbs are concomitantly used with P-gp substrate drugs as they may 
enhance their absorptive transport [28]. Frequently, antagonistic effects have been 
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reported on co-administration of herbals and orthodox medicines. For instance, although 
the leaves of Carica papaya (Pawpaw) are known to exhibit antimalarial effect, the 
antagonistic antimalarial properties when used in combination with artesunic acid in 
Plasmodium berghei-infected mice has been reported [78]. In the study, the extracts of 
Carica papaya when solely administered had good antimalarial activity. In a similar 
study, the influence of Eurycoma longifolia extract (Commonly known as Tongkat ali; a 
herbal remedy commonly used in malaria therapy) was investigated on 
co-administration with artemisinin (WHO’s recommended first-line antimalarial) in 
experimental mice. Findings from that study revealed the suppression of parasitemia in 
Plasmodium yoelii-infected mice. This is suggestive of a promising, potential 
antimalarial candidate by both oral and subcutaneous routes [79]. Similar synergistic 
herb-drug interactions involving goniothalamin (Goniothalamus 
scortechinii)-chloroquine, Vernonia amygdalina - chloroquine and curcumin (isolated 
from Curcuma longa) - artemisinin combinations have been documented with the 
suggestion that they be considered for future trials in the search for malaria combination 
therapy [80-82]. Also, herbs can be combined for their additive effect as shown by the 
mixture of a Khaya ivorensis (African mahogany) -Alstonia boonei (English alstonia) 
extract mixture as an antimalarial prophylactic remedy [83]. 
3.4 Liver diseases 
Hepatic disorders (including alcoholic liver disease, hepatitis, cirrhosis and steatosis) 
are still a cause for global concern [84]. Unfortunately, several orthodox drugs used in 
the management of liver diseases are inadequate and sometimes can have serious 
side effects. However, herbal medicines have been used in the treatment of liver 
diseases since ancient times. Silybum marianum (milk thistle) is a widely used herbal 
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remedy especially for the management of liver and gallbladder disorders [85]. Although 
preclinical evidence strongly supports its use as a hepatoprotectant, further 
well-designed clinical trials may be necessary to confirm this [86]. In-depth research 
has been conducted on its most active component- silymarin, a flavonoid complex. 
Silymarin and its active constituent, silybin, are believed to act as antioxidants, 
scavenging free radicals and inhibiting lipid peroxidation, thus finding use in chronic 
liver disorders [87, 88]. It is believed to be safe and well-tolerated, with very minor side 
effects reported when taken within the recommended dose range (gastrointestinal upset, 
mild laxative effect and rare allergic reaction). Because of its vast use, significant work 
has been carried out, examining the potential for herb-drug interactions. In a study by 
Gurley et al. (2006), [89] insignificant changes in the disposition of digoxin were 
observed on co-administration with silymarin, posing no clinically significant risk for 
P-gp-mediated herb-drug interactions. On the other hand, a study has shown that silybin 
A and silybin B at clinically relevant concentrations inhibit CYP 2C9-mediated 
metabolism of warfarin [90]. This HDI needs to be further evaluated because of the 
narrow therapeutic index of warfarin. In addition, there are several reports on the 
hepatoprotective function of glycyrrhizin (a major constituent of licorice). Besides 
inhibiting liver cell injury caused by many chemicals, it is also used in the treatment of 
chronic hepatitis and cirrhosis [91]. Glycyrrhizin has been shown to be a strong 
inhibitor of 11-β-hydroxysteroid dehydrogenase (the enzyme responsible for catalysing 
the conversion of cortisol to the inactive steroid cortisone) and is thought to alter the 
pharmacokinetics of prednisolone by inhibiting its metabolism. In one study, oral 




3.5 Asthma and Allergic diseases 
There are several reports on the use of herbal medicines in the treatment and 
management of asthma and allergic diseases (including allergic rhinitis, food allergy, 
and atopic dermatitis), which affect a high percentage of the population. Some of these 
phytomedicines are used alone, while some others are used in combination with 
conventional medicines. Corticosteroids are known to form a key component in the 
management of asthma and allergy. A study investigated the interaction potential of 
cortisol on concomitant administration with Glycyrrhiza glabra (licorice) and grapefruit 
juice. The findings showed significantly increased cortisol AUC and mean serum 
concentrations following the intake of licorice and grapefruit juice. Co-administration 
with grapefruit juice gave rise to a more complete intestinal absorption of cortisol 
during the first hours, indicative that interactions between various constituents and P-gp 
in the intestinal walls are implicated [93]. One study examined the relationship between 
the use of herbal medicines and adherence to inhaled corticosteroids. It was revealed 
that utilizing herbal medicines was associated with lower adherence to inhaled 
corticosteroids and poor outcomes among asthmatic patients probably due to patients 
worry over the adverse effects of the corticosteroids [94]. Petasites hybridus (Butterbur), 
a herbal remedy with antihistamine and anti-leukotriene activity conferred 
complementary anti-inflammatory activity in asthmatic patients who were receiving 
inhaled corticosteroids suggesting the potential benefit in asthma management [95]. 
Although theophylline is commonly utilized in asthma therapy, its use complicated by 
its interaction with several other drugs and its narrow therapeutic index. For instance in 
a study, its concomitant administration with St John’s wort has resulted in reduced 
plasma concentration of theophylline. [96]. However, in another clinical study in health 
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Japanese male volunteers, no significant alteration in the plasma pharmacokinetics of 
theophylline was observed when coadministered with St John’s wort [97]. Likewise 
there are reports on herb-drug interactions involving fexofenadine, a well known P-gp 
substrate probe which is commonly used in the management of allergy. A clinical study 
in healthy volunteers indicated a significant increase in the maximum plasma 
concentration of fexofenadine and a significant decrease in its oral clearance following 
the administration of a single dose of St John’s wort. In this study, no change in the 
half-life or renal clearance was observed [98]. This observation was also confirmed by 
another clinical study in healthy volunteers which demonstrated that pretreatment with 
St John’s wort significantly enhanced the oral clearance of fexofenadine by 1.6-fold. 
Here also, no alteration in the half-life was observed. The authors suggested the 
predominant inductive effect of St John’s wort on P-gp in the intestinal epithelium, 
which consequently caused a decrease in the absorbed fraction of oral fexofenadine [99]. 
As inhibition and induction of P-gp may significantly influence drug disposition, 
caution may need to be exercised in cases of their co-administration. 
3.6 Depression 
Several herbs have been used in the management of depression. Of particular note is 
Hypericum perforatum (St. John's wort) that has gained widespread popularity as 
“nature's Prozac”. It has been used for centuries as a natural remedy for the treatment of 
a number of diseases [100]. Some clinical studies have provided evidence that it is as 
effective as conventional antidepressants. Although the anti-depressive mechanism is 
not fully understood, its therapeutic effects have been confirmed in several studies when 
compared with placebo or standard antidepressant agents [101]. Even though it is 
widely obtained as an over-the-counter remedy, knowledge about the pharmacokinetics 
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of ingredients and drug interactions of St John's wort is not commensurate. Because of 
its ability to induce CYP 3A4/P-gp, there are some reports on its interaction with other 
CYP 3A/P-gp substrates leading to pharmacokinetic interaction with drugs known to 
have narrow therapeutic windows (E.g. Digoxin), to which therapeutic drug monitoring 
may be necessary [102]. Because several drugs are co-substrates of CYP 3A and P-gp, 
their disposition is markedly affected by concomitant administration of St John's wort 
through an activation of nuclear receptors, resulting in enhanced metabolism and efflux 
transport of the co-administered substrate drug to different extents depending on the 
relative contributions of CYP 3A and P-gp. For instance a study reported that the extent 
of induction measured by oral clearance was different with CYP3A activity 
(midazolam; which is solely metabolized by CYP 3A), which showed more increase 
than P-gp function (fexofenadine; a non-metabolized drug), whereas with cyclosporine 
(CYP 3A and P-gp are both importantly involved in its disposition), the change in oral 
clearance appeared to be more closely associated with the increase in MDR1 than with 
CYP 3A [99]. In general, most of these studies support the need for caution as well as 
stricter regulations of herbal medicines for safer drug therapy in medicine [103]. Panax 
ginseng is a widely used herbal medicine, notably used for its antidepressant effect. A 
study investigated the influence of Panax ginseng on CYP3A function using the probe 
midazolam as a substrate probe [104]. Comparison of pharmacokinetic parameter values 
of midazolam was calculated and compared before and following the administration of 
Panax ginseng. As illustrated in Figure 4, the findings revealed significant reduction for 
midazolam area under the concentration-time curve from zero to infinity, half-life and 
maximum concentration [104]. Also, American ginseng (Panax quinquefolius) 
reportedly reduces the effect of warfarin in healthy patients. This was observed in a 
21 
 
clinical study in healthy volunteers following a ginseng consumption for 2 weeks in 
which changes in the international normalized ratio, AUC, peak plasma warfarin level, 
and warfarin AUC were found to be statistically significantly greater in the group [105]. 
Here, the effect was postulated to be as a result of the inductive effect of ginseng on the 
hepatic drug metabolizing enzyme system, as warfarin is known to be metabolized by 
the CYP system. Green tea (from Camelia sinesis) is a popular beverage and dietary 
supplement with some reported interactions with conventional medicines. A study in 
healthy subjects examined its interaction potential with buspirone (a CYP3A4 substrate). 
The extract containing 800g epigallocatechin gallate was administered daily for 4 weeks 
to and was shown to significantly increase the bioavailability of buspirone [106]. Of 
note however is the fact that this cytochrome enzyme inhibition is unlikely to be of 
clinical relevance [106]. Another human study further revealed that a decaffeinated 
extract of green tea did not alter the pharmacokinetics of either dextromethorphan or 
alprazolam indicating the improbability of green tea to alter the disposition of CYP2D6 
or CYP3A4 substrates [107]. 
 
3.7 Other conditions 
Herbal medicines are also widely used in the management colds, infections and 
inflammation. For instance, echinacea is commonly used for the treatment of the 
common cold, coughs, bronchitis, influenza, and inflammation of the mouth and 
pharynx and is one of the most sold herbal medicines in use and is reportedly consumed 
by 10% to 20% of herbal users [25]. Because of its immuno-stimulatory effect, it is also 
commonly used for HIV and upper respiratory tract infections [108, 109]. In a study 
investigating the influence of Echinacea purpurea on the in vivo activity of CYP 
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isozymes (including CYP 3A4), after oral and intravenous midazolam administration, 
modulation of the catalytic activity of CYP 3A4 at both hepatic and intestinal sites were 
reported. Inhibition of intestinal CYP 3A4 activity was observed, with potent increase in 
midazolam’s oral bioavailability as well as significant enhancement of midazolam’s 
systemic clearance by inducing hepatic CYP 3A . In addition, the study advises the 
exercise of caution when it is co-administered with drugs that are dependent on CYP 3A 
or CYP 1A2 for their elimination [25].  
Similarly, studies investigating interactions of Ginkgo biloba (Maidenhair tree)- a 
herbal remedy commonly used for memory enhancement, have been reported. For 
instance, a human study revealed a significant increase in the bioavailability and peak 
plasma concentration of talinolol as a result of P-gp efflux inhibition, following 
long-term administration of ginkgo [110, 111].  This effect was suggested to be as a 
result of the P-gp inhibitory effect of some ginkgo flavonol constituents, including 
quercetin, kaempferol, and isorhamnetin, which have been documented [112]. In 
another study, the effect of the extract of Ginkgo biloba on midazolam (CYP 3A4 
substrate) and tolbutamide (CYP 2C9 substrate) was investigated [113]. There, the AUC 
of tolbutamide following ginkgo intake was significantly reduced. Conversely, the AUC 
of midazolam was significantly enhanced, while its oral clearance was decreased. 
However, another study reported the intestinal induction of CYP 3A4 following 
midazolam administration to healthy humans. After administration for 4 weeks, the 
bioavailability and maximum plasma concentration of midazolam significantly reduced 
with no change in the half-life suggestive of intestinal, but not hepatic, induction [113]. 
Another clinical study investigated the intake of the same dose of Ginkgo biloba extract 
after 2 weeks administration in combination with lopinavir, fexofenadine and 
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midazolam [114]. The CYP3A4 inductive effect of ginkgo was indicated by a 
significant decrease in the AUC and maximum plasma concentration of midazolam.  
However, neither lopinavir nor ritonavir pharmacokinetic parameter values were 
significantly altered. This is likely due to ritonavir's more potent inhibition of CYP3A4. 
It was therefore suggested that the Ginkgo biloba extract may unlikely reduce the 
exposure of ritonavir-boosted protease inhibitors, while concentrations of un-boosted 
protease inhibitors may be affected [114]. 
 
4. Draw-backs , surveillance and safety monitoring of herbal medicines  
Despite the fact that herbal medicines are widely used, the safety and efficacy profile of 
several of them are in doubt and unproven. Moreover, many consumers misinterpret the 
natural origin of herbal medicines as a sign of safety, without appreciating that herbal 
ingredients can cause serious adverse effects [115]. A major concern regarding the use 
of herbal medicines is their safety and toxicity profile. They may pose harm to patients 
under different circumstances through idiosyncratic or allergic reactions or the risk of 
herb-drug interaction occurring when taken concomitantly with conventional medicine. 
Because rigorous testing and regulatory agency approval is not routinely considered for 
many herbal medicines, they may be prone to easy adulteration or contamination, thus 
harmful. World over, several instances of toxicity have been reported on use of herbal 
medicines. Of significance is the development of kidney failure by several women in 
Belgium after taking slimming pills containing the herb Aristolochic fangchi. This 
further resulted in transitional cell carcinoma in some of these patients [116]. In addition, 
standardization of herbal medicines sometimes becomes challenging as their chemical 
makeup differs depending on the part of the plant used, growing conditions, periods of 
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harvest as well as the storage conditions.  Combination products composed of multiple 
natural products complicate matters further. In using herbal medicines, standardization, 
regulation and the scientific proof of patients’ safety are of paramount importance, 
especially in the development phase [117]. However, this is not the case in many 
instances and has resulted in the emergence of toxic responses.  
Although the use of herbal products is rapidly increasing, there are only few national 
surveillance systems monitoring and evaluating adverse reactions associated with their 
use [118]. In order to identify and assess the possible risks associated with herbal 
medicine use, pharmacovigilance studies are essential. For this, the establishment of 
pharmacovigilance centres would play a significant role in promoting awareness of 
herbal medicine safety and the need to report the observance of adverse drug reactions 
[119]. Pharmacovigilance encompasses the totality of monitoring drug safety including 
identifying plausible adverse drug interactions, assessing risks and benefits as well as 
conveying concerns over drug safety [120]. It is essential to regulate herbal medicine 
use as well as ensure appropriate quality control measures including quality 
specification, good manufacturing practices for herbal medicines, labeling and licensing 
schemes for manufacturing, imports and marketing should be enforced [121]. Also of 
importance is the need to extend knowledge on drug safety rather than the general 
approach of demonstrating toxicity. With an increased awareness and an increasing 
number of the populace utilizing herbal medicines, more and more toxicological 
assessments need to be being conducted. This is expected to include an investigation 
into the potential for genotoxicity, reproductive toxicity, hepatotoxicity, nephrotoxicity 
and neurotoxicity of the phytomedicines [122, 123]. There are recommendations 
concerning the need to strengthen expertise in toxicology as well as determining newer 
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approaches towards solving the present toxicological issues [124]. For example, the 
Caenorhabiditis elegans model has been proven to be a reliable and invaluable tool in 
toxicological assessments especially with respect to neurotoxic evaluations. In addition 
to its sharing a high sequence identity with several human genes as well as its 
anatomical and physiological characteristics, its genome has been fully sequenced and 
the nervous system has been extensively studied thereby making it of immense benefit 
in toxicological assessments [125]. 
 
5. Conclusion 
The use of herbal medicines is increasing, possibly due to their widespread promotion 
in the media as well as unsubstantiated health care claims. Although herbal medicines 
are beneficial, despite popular belief, they are not completely harmless and HDIs may 
occur on concomitant use with conventional drugs, but many possibly go unnoticed due 
to various factors.  It is safer to view them as unrefined pharmaceuticals, capable of 
producing physiologic change, for better or worse.  
Most herbal medicines, unlike conventional drugs comprise a complex mixture of 
chemical constituents.  In order to better understand the detection and handling of 
HDIs, an expansion on knowledge on phytochemicals in herbal medicines is essential. 
Presently in most cases, complete characterization of the bioactive compounds is not 
well defined, information on toxicity and adverse effects are insufficient. It is expected 
that standardization, including chemical fingerprinting would become potent tools for 
quality control of herbal medicines. However, because most of the available HDI 
information is based on individual case reports, animal studies and in vitro data, 
extensive research is required to confirm and assess the clinical significance of these 
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potential interactions. HDIs may be under-reported and appropriate pharmacovigilance 
requires the collective responsibility of the patient, the health practitioner and 
researchers.  
In this review, the pharmacokinetic (drug metabolizing enzymes and drug transporter 
systems) mechanisms have been considered to play a role in these interactions. There 
are reports on the inductive role of PXR as a nuclear receptor, however it is of 
importance to research into other receptors; constitutive androstane receptor (CAR), and 
vitamin D-binding receptor (VDR), as these may also play an integral role in the 
mechanism of inductive processes involved in HDIs. Future perspectives for the 
application of HDIs are in new drug development and use of herbal medicines as 
adjuvants to conventional drugs. They may also be used for their additive or synergistic 
effect when co-administered with modern medicine. This may require a decreased dose 
of the conventional drug, and possibly result to reduction in the manifestation of side 
effects. In particular, patients taking drugs with a narrow therapeutic index should be 
discouraged from using herbal products because of the ease of toxicity or 
ineffectiveness.  
In summary, HDIs certainly occur and may have serious consequences. However 
because they are under-researched, present knowledge is incomplete. It is worth 
mentioning that the further research and more controlled clinical studies are needed to 
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Table 1. Clinically relevant herb-drug interactions  
Disorder Conventional drug 
Herbal medicine Effect in human subjects Ref 
Cancer Imatinib St. John’s wort 
(Hypericum perforatum) 
43% ↑in imatinib clearance 
↓ of up to 32% mean area under the concentration–time 
curve 
significantly ↓ Cmax and half-life 
[49, 53, 54] 
Irinotecan St John’s wort 42% ↓ in plasma levels of the active metabolite of 
irinotecan 






Median number of leucocytes ↑ significantly in comparison to 






One case reporting a possible interaction between etoposide, 
and echinacea which resulted in trombocytopenia requiring a 
platelet transfusion 
[127] 
 Ginkgo (Ginkgo biloba)   
HIV/AIDS Saquinavir Garlic (Allium sativum) Signiﬁcantly decreases the systemic exposure 
↓ mean saquinavir AUC by 51% 
↓ Cmax by 54% 
[71] 
Indinavir St. John’s wort ↓ AUC0-8 of indinavir decreased by a mean of 57% 
49-99% ↓ in concentration 8 hr post-dosing 
↓ in the mean Cmax of indinavir from 12·3μg/mL to 8·9 μg/mL 
[68] 
Nevirapine St. John’s wort Clearance of nevirapine ↑ by 35% # [128] 
Protease 
inhibitors 
SP-303 (an extract of  
Croton lechler) 
Significant reduction of stool weight and stool frequency in 




Nifedipine Ginseng (Panax ginseng) ↑ Cmax of nifedipine by 29% [130] 
Simvastatin St. John’s wort 52% ↓ in AUC and 28% ↓ in Cmax # [131] 
Debrisoquin Goldenseal 
(Hydrastis canadensis) 
Goldenseal strongly inhibited CYP2D6 activity [132] 




Digoxin St John’s wort  10 days of treatment with St John’s wort ↓ digoxin AUC(0-24) 
by 25%  
[102] 
Diabetes Chlorpropamide Garlic ↑ hypoglycaemia [134] 
Asthma and allergy Fexofenadine St. John’s wort Single dose significantly ↑ Cp (max) of fexofenadine by 45% 
and significantly ↓ oral clearance by 20% * 
Long-term dose significantly ↓  Cp (max) of fexofenadine by 
35% and significantly ↑ oral clearance by 47% ¶ 
[98] 
Fexofenadine Grape fruit juice 
( Citrus paradisi) 
Consumption of grapefruit juice concomitantly or 2 h before 
fexofenadine administration was associated with ↓ oral fexofenadine 
plasma exposure 
[135] 
Fexofenadine Orange juice 
( Citrus sinensis) 
Orange juice ↓ the AUC, (Cmax) and the urinary excretion 
values fexofenadine  
[136] 
Thiazides Gingko ↑ blood pressure when combined with thiazide diuretics [134] 
Depression Midazolam Echinacea Significantly ↑ systemic clearance of midazolam by 34%, 
Significantly ↓ midazolam AUC by 23% 
Significantly ↑ oral availability of midazolam after echinacea 
dosing  
[25] 
Midazolam Goldenseal  Goldenseal strongly inhibited CYP3A4/5 activity [132] 













Ginkgo Potently inhibits platelet activating factor-mediated platelet 
aggregation 
↑ the ﬂuididity of blood 
[138-140] 







*, Proposed mechanism, inhibition of intestinal p-gp    ¶, Proposed mechanism, induction of p-gp 
#, Proposed mechanism, induction of CYP 3A4         §, Proposed mechanism, inhibition of intestinal p-gp
Warfarin St John’s wort ↓ anticoagulant effect of warfarin [141] 
Warfarin Ginseng Ginseng significantly ↓ warfarin’s anti-coagulant effect by ↓ 
the international normalized ratio (INR) and reducing plasma 
warfarin levels.  
[105] 
CNS stimulation Caffeine Echinacea Echinacea dosing significantly ↓ the oral clearance of caffeine [25] 
Immunosuppression Cyclosporin A St. John’s wort 46 % ↓ in AUC and 42 % ↓ in Cmax 
#, ¶ [142] 
Tacrolimus ↓ in AUC by 58% #, ¶ [143] 
Vitamin 
supplementation 
Folic acid Green tea  
(Camellia sinensis) 





Inhibition of  iron absorption in young women  [145] 
Antitussive Dextromethorphan Citrus aurantium 
Citrus paradisi 
Bioavailability of dextromethorphan increased significantly 
with grapefruit and seville orange juice*, § 
[146] 
Oral Contraception 
Norethindrone St John’s wort Significant ↑ in oral clearance of norethindrone, ↑ risk of 
unintended pregnancy and breakthrough bleeding 
[147] 
Ethinyl estradiol St John’s wort Significant ↓ in the half-life of ethinyl estradiol, ↑ risk of 








St John’s wort Increased serotonergic effects with risk of increased incidence of adverse reactions 
[137] 
Ulcers Omeprazole Gingko 
Significant ↓ in plasma concentrations of omeprazole and 









Illustration of the main mechanisms of herb-drug interactions with some examples. 
 
Figure 2 
Transporter expression in the main organs influencing drug disposition 
 
Figure 3 
Mean concentration-time profile of indinavir alone (solid line) and with concomitant St 
John's wort (dotted line), showing a large reduction in indinavir concentrations by 
concomitant St John's wort. In the study, fasting participants received indinavir 800 mg 
orally. They then received two more doses at 8 h intervals to achieve steady-state. On 
the morning of day 2, an 800 mg dose was given. On day 3, participants began 
treatment with St John's wort (300 mg three times daily) for 14 days. Piscitelli et al., 
2000. (Reproduced with permission from Elsevier) 
 
Figure 4 
Concentration-time profiles for midazolam (±SEM) before and after Panax 
ginseng administration. In this study, the pparticipants were administered a single 8-mg 
oral dose of midazolam syrup. They then began taking P ginseng at a dose of 500 mg 
twice daily for 28 days.  On day 28 of P ginseng administration, participants returned to 
the clinic for a repeat dose of midazolam. Malati et al., 2012. (Reproduced with 
permission from John Wiley & Sons, Inc) 
 
 
 
